IP Library Assignment 059788/0518
Patent Assignment
Reel/Frame 059788/0518

Assignment of Assignor's Interest

Recorded: 2022-04-25 Pages: 80
Assignor
TARVEDA THERAPEUTICS, INC.
Executed: 2022-04-15
Assignee
TVA (ABC), LLC
1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
Covered Properties (113)
Targeted Conjugates Encapsulated in Particles and Formulations Thereof
Application: 14/144,263 →
Publication: US 2014/0187501
Cabazitaxel-Platinum Nanoparticles and Methods of Using Same
Patent: 9,480,657 →
Application: 14/216,127 →
Publication: US 2014/0378427
Nanoparticle Diagnostic and Methods for Treating Disease
Application: 14/908,661 →
Publication: US 2016/0166715
Sstr-Targeted Conjugates Encapsulated in Particles and Formulations Thereof
Application: 14/949,138 →
Publication: US 2016/0074526
Targeted Therapeutics
Application: 15/314,769 →
Publication: US 2017/0136085
Targeted Conjugates and Particles and Formulations Thereof
Application: 15/319,738 →
Publication: US 2017/0151339
Targeted Conjugates and Particles and Formulations Thereof
Patent: 9,750,818 →
Application: 15/382,487 →
Publication: US 2017/0095569
Targeted Conjugates and Particles and Formulations Thereof
Application: 15/652,947 →
Publication: US 2018/0000959
Targeted Conjugates and Particles and Formulations Thereof
Application: 15/652,957 →
Publication: US 2017/0312245
Targeted Conjugates Encapsulated in Particles and Formulations Thereof
Application: 15/695,214 →
Publication: US 2018/0021454
Combination Therapy
Application: 15/734,110 →
Publication: US 2021/0186978
Targeted Conjugates and Particles and Formulations Thereof
Application: 15/737,084 →
Publication: US 2019/0125888
Compositions and Methods for Immuno-Oncology Therapies
Application: 15/749,180 →
Publication: US 2018/0221503
Compositions and Methods for Immunomodulation
Application: 15/749,194 →
Publication: US 2018/0221508
Compositions and Methods for Genome Editing
Application: 15/762,627 →
Publication: US 2018/0258411
RNAi CONJUGATES, PARTICLES AND FORMULATIONS THEREOF
Application: 15/762,635 →
Publication: US 2018/0273948
Sstr-Targeted Conjugates and Particles and Formulations Thereof
Application: 15/770,513 →
Publication: US 2018/0221499
Targeted Constructs and Formulations Thereof
Application: 15/952,275 →
Publication: US 2018/0296685
Stapled Peptide Conjugates and Particles
Application: 16/075,292 →
Publication: US 2019/0365913
HSP90 Targeted Conjugates and Particles and Formulations Thereof
Application: 16/079,387 →
Publication: US 2019/0054072
Antibody Mimic Conjugates and Particles
Application: 16/085,398 →
Publication: US 2019/0085034
Neurotensin Receptor Binding Conjugates and Formulations Thereof
Application: 16/093,233 →
Publication: US 2020/0078468
Targeted Constructs and Formulations Thereof
Application: 16/301,144 →
Publication: US 2020/0009262
Sstr-Targeted Conjugates and Particles and Formulations Thereof
Application: 16/345,306 →
Publication: US 2019/0262460
Nanoparticle Diagnostic and Methods for Treating Disease
Application: 16/381,332 →
Publication: US 2019/0231906
HSP90-Targeting Conjugates and Formulations Thereof
Application: 16/469,768 →
Publication: US 2020/0085960
Targeted Therapeutics
Application: 16/625,358 →
Publication: US 2020/0230126
Combination Therapies Comprising Targeted Therapeutics
Application: 16/625,362 →
Publication: US 2020/0230247
HSP90 Targeted Conjugates and Particle Formulations Thereof
Application: 16/625,368 →
Publication: US 2020/0237746
HSP90 Targeted Conjugates and Particles and Formulations Thereof
Application: 16/711,577 →
Publication: US 2020/0113877
Sstr-Targeted Conjugates Encapsulated in Particles and Formulations Thereof
Application: 16/722,913 →
Publication: US 2020/0121808
Sstr-Targeted Conjugates and Formulations Thereof
Application: 16/759,438 →
Publication: US 2020/0281934
HSP90-Targeting Conjugates and Formulations Thereof
Application: 16/772,290 →
Publication: US 2021/0000966
Targeted Conjugates and Particles and Formulations Thereof
Application: 16/793,094 →
Publication: US 2020/0206356
RNAi CONJUGATES, PARTICLES AND FORMULATIONS THEREOF
Application: 16/921,390 →
Publication: US 2020/0339990
HSP90-Targeting Conjugates and Formulations Thereof
Application: 17/045,320 →
Publication: US 2021/0145971
Pharmaceutical Compositions with Reduced Tert-Butanol Levels
Application: 17/045,325 →
Publication: US 2021/0169871
HSP90-Targeting Conjugates and Formulations Thereof
Application: 17/275,748 →
Publication: US 2022/0031853
Sstr-Targeted Conjugates and Particles and Formulations Thereof
Application: 17/490,692 →
Publication: US 2022/0096646
Sstr-Targeted Conjugates and Particles and Formulations Thereof
Application: 17/518,794 →
Publication: US 2022/0054647
HSP90-Targeting Conjugates and Formulations Thereof
Application: 17/546,706 →
Publication: US 2022/0096640
HSP90-Binding Conjugates and Formulations Thereof
Application: 17/600,692 →
Publication: US 2022/0184217
Sstr-Targeted Conjugates and Formulations Thereof
Application: 17/618,759 →
Publication: US 2022/0257766
HSP90-Binding Conjugates and Combination Therapies Thereof
Application: 17/618,761 →
Publication: US 2022/0257777
Nanoparticulate Targeted Drug Delivery
Application: 61/746,866 →
Cabazitaxel-Platinum Nanoparticles and Methods of Using Same
Application: 61/792,665 →
Nanoparticle Diagnostic and Methods for Treating Disease
Application: 61/859,826 →
Targeted Therapeutics
Application: 62/004,519 →
Targeted Conjugates Encapsulated in Particles and Formulations Thereof
Application: 62/019,001 →
Targeted Conjugates Encapsulated in Particles and Formulations Thereof
Application: 62/019,003 →
Particles Incorporating Drug Conjugates of Targeting Scaffolds and Formulations Thereof
Application: 62/020,615 →
Targeted Conjugates Encapsulated in Particles and Formulations Thereof
Application: 62/077,487 →
Targeted Conjugates Encapsulated in Particles and Formulations Thereof
Application: 62/084,306 →
Targeted Conjugates and Particles and Formulations Thereof
Application: 62/102,261 →
Targeted Conjugates and Particles and Formulations Thereof
Application: 62/150,413 →
Targeted Conjugates and Particles and Formulations Thereof
Application: 62/186,657 →
Compositions and Methods for Immuno-Oncology Therapies
Application: 62/199,414 →
Compositions and Methods for Immunomodulation
Application: 62/199,422 →
RNAi CONJUGATES, PARTICLES AND FORMULATIONS THEREOF
Application: 62/232,627 →
Sstr-Targeted Conjugates and Particles and Formulations Thereof
Application: 62/247,336 →
Stapled Peptide Conjugates and Particles
Application: 62/291,212 →
HSP90 Targeted Conjugates and Particles and Formulations Thereof
Application: 62/298,917 →
Sstr-Targeted Conjugates and Particles and Formulations Thereof
Application: 62/304,856 →
Antibody Mimic Conjugates and Particles
Application: 62/308,908 →
Conjugates of Biased Agonists and Particles and Formulations Thereof
Application: 62/322,173 →
Compositions and Methods for Immuno-Oncology Therapies
Application: 62/332,772 →
Compositions and Methods for Immunomodulation
Application: 62/332,838 →
Targeted Constructs and Formulations Thereof
Application: 62/336,120 →
Penicillamine Conjugates and Particles and Formulations Thereof
Application: 62/343,445 →
HSP90 Targeted Conjugates and Particles and Formulations Thereof
Application: 62/351,716 →
T Cell Binding Conjugates and Methods of Use
Application: 62/368,632 →
Sstr-Targeted Conjugates and Particles and Formulations Thereof
Application: 62/414,481 →
HSP90-Targeting Conjugates and Formulations Thereof
Application: 62/434,282 →
HSP90-Targeting Conjugates and Formulations Thereof
Application: 62/449,260 →
Targeted Constructs and Formulations Thereof
Application: 62/476,123 →
Neurotensin Conjugates and Formulations Thereof
Application: 62/476,132 →
Targeted Constructs and Formulations Thereof
Application: 62/485,064 →
HSP90-Targeting Conjugates and Formulations Thereof
Application: 62/487,726 →
Fcrn-Binding Antibody Mimetics and Targeted Constructs
Application: 62/513,842 →
Antibody Mimetics and Targeted Constructs
Application: 62/513,882 →
Targeted Therapeutics
Application: 62/522,316 →
Combination Therapies Comprising Targeted Therapeutics
Application: 62/522,323 →
HSP90 Targeted Conjugates and Particle Formulations Thereof
Application: 62/522,333 →
Targeted Constructs
Application: 62/535,347 →
Sstr-Targeted Conjugates and Particles and Formulations Thereof
Application: 62/577,897 →
HSP90-Targeting Conjugates and Formulations Thereof
Application: 62/598,755 →
Targeted Constructs
Application: 62/599,352 →
Targeted Therapeutics
Application: 62/642,154 →
Targeted Constructs
Application: 62/653,093 →
HSP90-Targeting Conjugates and Formulations Thereof
Application: 62/653,106 →
Pharmaceutical Compositions with Reduced Tert-Butanol Levels
Application: 62/653,118 →
Combination Therapy
Application: 62/679,216 →
Combination Therapies Comprising Targeted Therapeutics
Application: 62/679,224 →
Sstr-Targeted Conjugates and Formulations Thereof
Application: 62/679,230 →
HSP90-Targeting Conjugates and Formulations Thereof
Application: 62/684,666 →
HSP90-Targeting Conjugates and Formulations Thereof
Application: 62/731,538 →
HSP90-Targeting Conjugates and Formulations Thereof
Application: 62/731,543 →
HSP90-Targeting Conjugates and Formulations Thereof
Application: 62/731,545 →
HSP90-Targeting Conjugates and Formulations Thereof
Application: 62/735,306 →
HSP90-Targeting Conjugates and Formulations Thereof
Application: 62/757,955 →
HSP90-Targeting Conjugates and Formulations Thereof
Application: 62/787,799 →
Combination Therapy
Application: 62/788,326 →
Combination Therapy
Application: 62/827,232 →
HSP90-Targeting Conjugates and Formulations Thereof
Application: 62/828,645 →
Sstr-Targeted Conjugates and Formulations Thereof
Application: 62/866,134 →
HSP90-Binding Conjugates and Combination Therapies Thereof
Application: 62/866,140 →
Targeted Therapeutics
Application: 62/899,777 →
HSP90-Binding Conjugates and Formulations Thereof
Application: 62/986,245 →
HSP90-Binding Conjugates and Formulations Thereof
Application: 63/003,528 →
HSP90-Binding Conjugates and Combination Therapies Thereof
Application: 63/035,048 →
HSP90-Binding Conjugates and Formulations Thereof
Application: 63/070,418 →
HSP90-Binding Conjugates and Formulations Thereof
Application: 63/184,348 →
HSP90-Binding Conjugates and Formulations Thereof
Application: 63/184,352 →
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Apr 14, 2014
From: BILODEAU, MARK T.; KADIYALA, SUDHAKAR; SHINDE, RAJESH; WHITE, BRIAN
To: BLEND THERAPEUTICS, INC.
Reel/Frame 032663/0189 →
Assignment of Assignor's Interest Jul 8, 2014
From: BILODEAU, MARK T.; DUNBAR, CRAIG A.; BARDER, TIMOTHY E.; LEE, EDWARD R.
To: BLEND THERAPEUTICS
Reel/Frame 033262/0769 →
Corrective Assignment to Correct the Receiving Party Name Previously Recorded at Reel: 033262 Frame: 0769. Assignor(S) Hereby Confirms the Assignment. Apr 16, 2015
From: BILODEAU, MARK T.; DUNBAR, CRAIG A.; BARDER, TIMOTHY E.; LEE, EDWARD R.
To: BLEND THERAPEUTICS, INC.
Reel/Frame 035444/0319 →
Assignment of Assignor's Interest Jan 21, 2016
From: BILODEAU, MARK T.; KADIYALA, SUDHAKAR; SHINDE, RAJESH; WHITE, BRIAN
To: BLEND THERAPEUTICS, INC.
Reel/Frame 037545/0592 →
Change of Name Jan 28, 2016
From: BLEND THERAPEUTICS, INC.
To: TARVEDA THERAPEUTICS, INC.
Reel/Frame 037629/0907 →
Assignment of Assignor's Interest Feb 1, 2016
From: KADIYALA, SUDHAKAR; LIM SOO, PATRICK; IWICKI, MARK; DUNBAR, CRAIG
To: BLEND THERAPEUTICS, INC.
Reel/Frame 037632/0062 →
Change of Name Feb 2, 2016
From: BLEND THERAPEUTICS, INC.
To: TARVEDA THERAPEUTICS, INC.
Reel/Frame 037680/0907 →
Change of Name Jan 11, 2017
From: BLEND THERAPEUTICS, INC.
To: TARVEDA THERAPEUTICS, INC.
Reel/Frame 041343/0936 →
Assignment of Assignor's Interest Jan 11, 2017
From: WHITE, BRIAN H.; ALARGOVA, ROSSITZA G.; BAZINET, PATRICK ROSAIRE; DUNBAR, CRAIG A.
To: BLEND THERAPEUTICS, INC.
Reel/Frame 041343/0882 →
Change of Name Jan 26, 2017
From: SYNTA PHARMACEUTICALS CORP.
To: MADRIGAL PHARMACEUTICALS, INC.
Reel/Frame 041511/0666 →
Assignment of Assignor's Interest Jan 26, 2017
From: CHEN, SHOUJUN; LU, GENLIANG; OSMAN, SAMI
To: SYNTA PHARMACEUTICALS CORP.
Reel/Frame 041097/0973 →
Assignment of Assignor's Interest Apr 10, 2017
From: ALARGOVA, ROSSITZA G.; BILODEAU, MARK T.; DUNBAR, CRAIG A.; KADIYALA, SUDHAKAR
To: BLEND THERAPEUTICS, INC.
Reel/Frame 041948/0908 →
Change of Name Apr 10, 2017
From: BLEND THERAPEUTICS, INC.
To: TARVEDA THERAPEUTICS, INC.
Reel/Frame 042201/0282 →
Change of Name Jul 20, 2017
From: BLEND THERAPEUTICS, INC.
To: TARVEDA THERAPEUTICS, INC.
Reel/Frame 043269/0688 →
Change of Name Jul 20, 2017
From: BLEND THERAPEUTICS, INC.
To: TARVEDA THERAPEUTICS, INC.
Reel/Frame 043269/0617 →
Assignment of Assignor's Interest Jul 20, 2017
From: ALARGOVA, ROSSITZA G.; BILODEAU, MARK T.; DUNBAR, CRAIG A.; KADIYALA, SUDHAKAR
To: BLEND THERAPEUTICS, INC.
Reel/Frame 043052/0964 →
Assignment of Assignor's Interest Jul 20, 2017
From: ALARGOVA, ROSSITZA G.; BILODEAU, MARK T.; DUNBAR, CRAIG A.; KADIYALA, SUDHAKAR
To: BLEND THERAPEUTICS, INC.
Reel/Frame 043052/0879 →
Change of Name Sep 6, 2017
From: BLEND THERAPEUTICS, INC.
To: TARVEDA THERAPEUTICS, INC.
Reel/Frame 043762/0299 →
Assignment of Assignor's Interest Sep 6, 2017
From: BILODEAU, MARK T.; KADIYALA, SUDHAKAR; SHINDE, RAJESH; WHITE, BRIAN
To: BLEND THERAPEUTICS, INC.
Reel/Frame 043495/0338 →
Assignment of Assignor's Interest Nov 7, 2017
From: MOREAU, BENOÎT
To: BLEND THERAPEUTICS, INC.
Reel/Frame 044055/0331 →
Change of Name Nov 7, 2017
From: BLEND THERAPEUTICS, INC.
To: TARVEDA THERAPEUTICS, INC.
Reel/Frame 044392/0474 →
Change of Name Nov 8, 2017
From: BLEND THERAPEUTICS, INC
To: TARVEDA THERAPEUTICS, INC.
Reel/Frame 044722/0971 →
Assignment of Assignor's Interest Nov 8, 2017
From: MOREAU, BENOÎT
To: BLEND THERAPEUTICS, INC.
Reel/Frame 044073/0959 →
Assignment of Assignor's Interest Jan 9, 2018
From: WHITE, BRIAN H.; BILODEAU, MARK T.; MOREAU, BENOÎT; SHINDE, RAJESH R.
To: TARVEDA THERAPEUTICS, INC.
Reel/Frame 044574/0772 →
Assignment of Assignor's Interest Jan 31, 2018
From: KADIYALA, SUDHAKAR; WARD, DONNA T.; WOOSTER, RICHARD
To: TARVEDA THERAPEUTICS, INC.
Reel/Frame 044782/0052 →